Illumina (NASDAQ:ILMN) Reaches New 52-Week High Following Analyst Upgrade

Illumina, Inc. (NASDAQ:ILMN) shares reached a new 52-week high on Monday after Royal Bank Of Canada raised their price target on the stock from $230.00 to $310.00. Royal Bank Of Canada currently has an outperform rating on the stock. Illumina traded as high as $281.46 and last traded at $282.5770, with a volume of 803535 shares. The stock had previously closed at $273.04.

Several other research firms also recently commented on ILMN. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 1st. Barclays raised their price target on shares of Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research report on Friday, July 31st. Stifel Nicolaus lifted their price target on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. UBS Group raised Illumina from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $135.00 to $260.00 in a report on Wednesday, September 9th. Finally, Sanford C. Bernstein reissued a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a research note on Friday, July 31st. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $219.69.

Insider Transactions at Illumina

In other news, SVP Christensen Wedel sold 1,033 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. The trade was a 6.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $218.40, for a total value of $26,099,018.40. Following the completion of the transaction, the director owned 770,350 shares in the company, valued at $168,244,440. The trade was a 13.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 2,061,850 shares of company stock valued at $436,479,102 over the last ninety days. 2.90% of the stock is currently owned by insiders.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Analyst optimism remains a key support. RBC Capital Markets raised its price target to $310 from $230 and maintained an “outperform” rating, citing improving clinical sequencing demand. RBC also characterized clinical sequencing revenue as a durable mid-teens growth opportunity. Illumina clinical sequencing revenue article
• Positive Sentiment: The recent rally was fueled by expectations for stronger clinical sales, additional business catalysts, and a potential role for genomic sequencing data as artificial-intelligence infrastructure. Illumina’s September addition to the S&P 500 may also support demand from index-tracking funds. Illumina shares rally article
• Neutral Sentiment: Illumina’s latest reported quarter exceeded consensus expectations for both earnings and revenue, while management raised full-year 2026 adjusted EPS guidance to $5.30–$5.40. These fundamentals provide longer-term support, although investors are now weighing them against the stock’s elevated valuation.
• Negative Sentiment: Barclays raised its price target to $200 from $160 but retained an underweight rating. The target remains well below recent trading levels, signaling that the bank believes expectations and valuation have outpaced near-term fundamentals. Barclays Illumina price target article
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, including substantial sales attributed to Keith Meister. While insider transactions do not necessarily reflect operating performance, the selling may add to investor caution after the recent surge. Illumina momentum and insider activity article

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Fiduciary Financial Advisors purchased a new stake in shares of Illumina during the 2nd quarter valued at $26,000. MCF Advisors LLC boosted its holdings in shares of Illumina by 172.4% in the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after buying an additional 100 shares during the last quarter. Keating Financial Advisory Services Inc. bought a new position in Illumina during the second quarter valued at about $32,000. Rakuten Securities Inc. bought a new position in Illumina during the second quarter valued at about $33,000. Finally, Elevation Wealth Partners LLC grew its position in Illumina by 52.5% during the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after buying an additional 84 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

The business’s fifty day moving average is $223.07 and its 200-day moving average is $178.23. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The firm has a market cap of $41.30 billion, a PE ratio of 51.03, a P/E/G ratio of 4.16 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same period in the previous year, the company earned $1.19 earnings per share. The company’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.